Relenza, a pandemic flu vaccine made by GlaxoSmithKline has been approved for sale in China. It will be the second imported anti-virus drug approved by China's State Food and Drug Administration or SFDA. Relenza directly effects the upper respiratory tract. It's effective against both the influenza A and B virus. It's one of the leading drugs recommended by the World Health Organization. Another kind of anti-flu vaccine sold on the mainland market, is Tamiflu made by Roche of Switzerland. The import of Relenza extends China's anti-flu prevention work and its use would lower the number of fatalities from flu.